1 vascular injury expert working group biomarkers of drug-induced vascular injury ncss 10 september...
Post on 13-Dec-2015
235 Views
Preview:
TRANSCRIPT
1
Vascular Injury Expert Working Group
Biomarkers of Drug-Induced Vascular Injury
NCSS 10 September 02 Report
2
Vascular InjuryExpert Working Group
Committee Members• Bill Kerns, Pharma Consulting-CoChair• Les Schwartz, GlaxoSmithKline-CoChair• David Essayan, CBER• Don Robertson, Pfizer• Fred Miller, NIEHS• Kerry Blanchard, Boehringer-Ingleheim• Jim MacGregor, NCTR
3
Vascular InjuryExpert Working Group
Committee Members• Frank Sistare, CDER• Paul Snyder, Purdue• Prakash Nagarkatti, Virginia Common. Univ.• Robert Johnson, Schering-Plough• Scott Burchiel, University of New Mexico• Tom Papoian, CDER
4
Vascular InjuryExpert Working Group
Active Contributors• Eric Fung-Ciphergen• Mike Lawton-Pfizer• Calvert Louden-AstraZeneca• Heath Thomas-GlaxoSmithKline• Anthony Ward-BD Biosciences• Jun Zhang-CDER
5
Vascular InjuryExpert Working Group
• Meetings– 31 July 01 conference call– 9 October 01 conference call– 7 November 01 meeting at ACT– 13 November 01 NCSS report– 25 February 02 conference call– 12 March 02 conference call– 20 March 02 meeting at SOT– 10 June 02 NCSS report– 27 June 02 conference call– 22/23 July 02 meeting at FDA
6
Vascular InjuryExpert Working Group
• Meetings– 8 August NCTR– 9/10 Sept NCSS– Sept Conference Call– Nov-ACT Meeting
7
Vascular InjuryExpert Working Group
Today’s Objectives• Review EWG Mandate• Why is vascular injury in animals an issue?• Review EWG progress to date• Review discussion points and get feedback
from NCSS on next steps
8
EWG Mandate
• Evaluate and develop a current understanding of vascular injury in animals and humans
• Identify opportunities for biomarkers based on probable mechanisms
• Develop validation plans
• Transition new markers from animals to Phase 1
9
Issue
• drug-induced microscopic polyangitis (hypersensitivity angitis) and leukocytoclastic angitis of humans is not, or rarely, observed in toxicology studies
• current animal models are poor predictors of drug-induced angitis in humans
• common drug-induced vascular lesions in animals are “not known” to occur in humans and have unknown relevance
• lesions in animals occur in areas that are prone to spontaneous vascular disease
10
Rat MesenteryDA 1 Agonist
11
Rat MesenteryDA 1 Agonist
12
Rat MesenteryDA 1 Agonist
13
Rat MesenteryDA 1 Agonist
14
2 yr old rat
15
CanineIdiopathic Polyarteritis
16Human-HypersensitivityAngitis
17
Normal Physiology
endothelium
IEL
SMC
18
Normal Physiology
Shear Stress (t=F/A)
(t=32μQ/πD3)
endothelium
IEL
SMC
blood flow
endothelium
19
Normal Physiology
Hoop Stress (σ=PR/h)
endothelium
IEL
SMC
endothelium
20
Acute Drug-Induced Vascular Injury
Selectins ICAM-1VCAM-1 PECAM
IEL
SMC
MCP-1, RANTES, IL-1, IL-8. TNFa, CD62P, INFg, LPS, ...
edema
21
Acute Drug-Induced Vascular Injury
Selectins ICAM-1VCAM-1 PECAM
endothelium
IEL
SMC
IL-1, IL-8. TNFa, ECF...
edema
22
Potential Mechanisms
• Biomechanical injury following changes in shear or tension
• Direct pharmacological or chemical perturbation
• Immune-mediated
23
Summary
• regardless of mechanism, endothelial compromise appears as an early event in rats and dogs
• drug-induced lesions in the rat and dog appear in sites of spontaneous disease, further complicating interpretation of toxicology studies
24
Summary
• common drug-induced vascular injury of humans is not, or rarely, observed in toxicology studies
• common drug-induced vascular lesions in animals are “not known” to occur in humans and have unknown relevance
• there are, however, no validated methods for detecting drug-induced vascular injury in animals or humans
25
Q&A
Is the problem clear?
The EWG confirms that this is an issue that requires resolution.
26
Progress to Date• thoroughly educated group on the issue• agreed standard rat protocol
– need more discussion on data management, protocol review, centralized analyses
• agreed standard compounds for inducing vascular injury (fenoldopam, PDE IV, dopamine)
• crafted a list of potential biomarkers• sE selectin proposal for review• new research data from contributing
companies is emerging monthly
27
Potential Biomarker Targets
• Injury Phase– Apoptosis markers (sCD44, sFASL)– Circulating endothelial cells (CD31 or Annexin)
• Inflammatory Phase– Acute Phase Proteins (α2, haptoglobin, fibrinogen,
CRP)– HA, eSelectin, thrombomodulin, vWF, ET-1, TNF,
IL-6, IL-1beta, tryptase, MPO
• Genomics/Proteomics/Metabonomics– Gene expression mapping. Endothelial cells and
vascular smooth muscle cells– Urinary or plasma NMR spectra
28
Biomarkers: Early Leads
• Urinary NMR (Pfizer)
• Circulating endothelial cells (GSK)
• Acute phase proteins (FDA, BI)
• sE-selectin (CD62E)
29
Discussion PointsDraft White Paper• Plan to polish and submit for publication
– Stimulate interest– Let public know what FDA and industry are doing– What is formal process for NCSS to ratify our final
draft
• Comments on content/organisation
30
Discussion PointsNCSS/NCTR• develop collaborations between FDA/industry
and NCTR to support genomics, proteomics and metabonomics with tissues from standard studies done by collaborators
• comments• what is process?• CRADA
31
Discussion Points• Letter to Abbot and Pfizer for drug supplies
– Approval process?– How do we manage drug distrbution?
• Organise Oct 2003 symposium– Comments– Process
• Biomarkers identified to date– Comments
• Develop reagents, broad data sets, and high potential targets for further validation– Comments– Process ($$)
32
Timeline-13 Nov 01
• February 2002– Agree on study protocols and endpoints– Agree on model compounds– Agree on collaborative responsibilities
• March 2002– Finalize a terminology position/document – Define budget for sourcing study compounds– Review any new data from committee– Finalize plans for NCTR and Pharma support and
any other support
33
Timeline-13 Nov 01• April 2002-March 2003
– Initiate standard protocol studies– Acquire model compounds– Organize data centrally
• March 2003– Review first data sets from multiple standardized
experiments– Develop plans and timeline for guidance
recommendations
• October 2003– symposium
• November 2003– Target date for initial biomarker (s) recommendation for
validation
top related